Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 9/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30954981 | 1.00 | NR1H2 (0.42) | NR1H2USP2SMN1; SMN2DDB1CRBN | |
| SCHEMBL15719645 | 1.00 | NR1H2 (0.42) | NR1H2USP2SMN1; SMN2DDB1CRBN | |
| SCHEMBL31722107 | 1.00 | NR1H2 (0.42) | NR1H2USP2SMN1; SMN2DDB1CRBN | |
| SCHEMBL30609275 | 0.84 | USP2 (0.41) | NR1H2USP2SMN1; SMN2DDB1CRBN | |
| SCHEMBL17966333 | 0.84 | HPGD (0.46) | USP2SMN1; SMN2HPGDRECQL | |
| SCHEMBL27005788 | 0.84 | USP2 (0.41) | NR1H2USP2SMN1; SMN2DDB1CRBN | |
| SCHEMBL518564 | 0.84 | HPGD (0.46) | USP2SMN1; SMN2HPGDRECQL | |
| SCHEMBL2348147 | 0.84 | USP2 (0.41) | NR1H2USP2SMN1; SMN2DDB1CRBN | |
| SCHEMBL31363576 | 0.84 | NR1H2 (0.40) | NR1H2USP2SMN1; SMN2RORCHPGD | |
| SCHEMBL17966308 | 0.84 | HPGD (0.46) | USP2SMN1; SMN2HPGDRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4695230-A1 | PROTEASE INHIBITORS AND USES THEREOF | Westlake Pharmaceuticals (Hangzhou) Co., Ltd. (CN) | 2026-02-18 | — | — | EP | disclosed |
| EP-4402138-B1 | 3-PHENOXYAZETIDIN-1-YL-HETEROARYL PYRROLIDINE DERIVATIVES AND THE USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM INT (DE) | 2025-08-27 | — | — | EP | disclosed |
| WO-2024212101-A1 | PROTEASE INHIBITORS AND USES THEREOF | WESTLAKE PHARMACEUTICALS (HANGZHOU) CO., LTD. (CN) | 2024-10-17 | — | — | WO | disclosed |
| US-12115157-B2 | 3-phenoxyazetidin-1-yl-heteroaryl pyrrolidine derivatives and the use thereof as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-10-15 | — | — | US | disclosed |
| EP-4402138-A1 | 3-PHENOXYAZETIDIN-1-YL-HETEROARYL PYRROLIDINE DERIVATIVES AND THE USE THEREOF AS MEDICAMENT | Boehringer Ingelheim International GmbH (DE) | 2024-07-24 | — | — | EP | disclosed |
| CN-117940420-A | 3-Phenoxyazetidin-1-yl-heteroaryl pyrrolidine derivatives and their use as pharmaceuticals | 勃林格殷格翰国际有限公司 | 2024-04-26 | — | — | CN | disclosed |
| US-20230131465-A1 | 3-PHENOXYAZETIDIN-1-YL-HETEROARYL PYRROLIDINE DERIVATIVES AND THE USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-04-27 | — | — | US | disclosed |
| US-20230131465-A1 | 3-PHENOXYAZETIDIN-1-YL-HETEROARYL PYRROLIDINE DERIVATIVES AND THE USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-04-27 | — | — | US | disclosed |
| US-20230131465-A1 | 3-PHENOXYAZETIDIN-1-YL-HETEROARYL PYRROLIDINE DERIVATIVES AND THE USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-04-27 | — | — | US | disclosed |
| WO-2023041432-A1 | 3-PHENOXYAZETIDIN-1-YL-HETEROARYL PYRROLIDINE DERIVATIVES AND THE USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-03-23 | — | — | WO | disclosed |
| EP-3810606-A1 | THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE | UCB Biopharma SRL (BE) | 2021-04-28 | — | — | EP | disclosed |
| WO-2019243550-A1 | THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE | UCB Biopharma SRL (BE) | 2019-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12115157-B2 | 3-phenoxyazetidin-1-yl-heteroaryl pyrrolidine derivatives and the use thereof as medicament | GPR52, GPR88, GPR68 | NR1H2 246/4885USP2 2611/4885SMN1; SMN2 2515/4885 |
| US-20230131465-A1 | 3-PHENOXYAZETIDIN-1-YL-HETEROARYL PYRROLIDINE DERIVATIVES AND THE USE THEREOF AS MEDICAMENT | GPR52, GPR88, GPR68 | NR1H2 246/4885USP2 2611/4885SMN1; SMN2 2515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.